The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.

ABSTRACT:

Objective

To estimate the economic burden of systematic lupus erythematous (SLE), stratified by disease severity, in commercially- and Medicaid-insured US populations.

Methods

Adults (≥18 years) with SLE treated with antimalarials, selected biologics, immunosuppressants, and systemic glucocorticoids (2010-2014) were identified within the commercial and Medicaid insurance IBM MarketScan® databases (index date = first SLE medication claim). Both cohorts were stratified into mild (receiving antimalarial or glucocorticoid monotherapy ≤5 mg/day) versus moderate/severe SLE (receiving glucocorticoids >5 mg/day, biologic, immunosuppressant, or combination therapy) during a 6-month exposure period. All-cause healthcare utilization and costs were evaluated during the 12 months followi

SUBMITTER: Clarke AE 

PROVIDER: S-EPMC7857313 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature